DK3534880T3 - Flydende oral farmaceutisk dosisform omfattende en histamin-h2-receptor-antagonist og et syreneutraliserende middel - Google Patents
Flydende oral farmaceutisk dosisform omfattende en histamin-h2-receptor-antagonist og et syreneutraliserende middel Download PDFInfo
- Publication number
- DK3534880T3 DK3534880T3 DK17817874.5T DK17817874T DK3534880T3 DK 3534880 T3 DK3534880 T3 DK 3534880T3 DK 17817874 T DK17817874 T DK 17817874T DK 3534880 T3 DK3534880 T3 DK 3534880T3
- Authority
- DK
- Denmark
- Prior art keywords
- histamine
- dosage form
- receptor antagonist
- pharmaceutical dosage
- neutralizing agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1651441 | 2016-11-01 | ||
| PCT/IB2017/056730 WO2018083583A1 (en) | 2016-11-01 | 2017-10-30 | Liquid oral pharmaceutical dosage form comprising an histamine h2-receptor antagonist and an antacid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3534880T3 true DK3534880T3 (da) | 2022-07-25 |
Family
ID=60766008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17817874.5T DK3534880T3 (da) | 2016-11-01 | 2017-10-30 | Flydende oral farmaceutisk dosisform omfattende en histamin-h2-receptor-antagonist og et syreneutraliserende middel |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200038376A1 (da) |
| EP (1) | EP3534880B1 (da) |
| CN (1) | CN109890368B (da) |
| AU (1) | AU2017353968B2 (da) |
| CA (1) | CA3042466A1 (da) |
| DK (1) | DK3534880T3 (da) |
| MA (1) | MA46713A (da) |
| RU (1) | RU2761346C2 (da) |
| WO (1) | WO2018083583A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095103A1 (en) | 2018-04-27 | 2019-10-31 | Johnson & Johnson Consumer Inc. | Liquid oral pharmaceutical dosage form |
| CN112822998A (zh) * | 2018-10-18 | 2021-05-18 | 强生消费者公司 | 新型剂型 |
| CN114340599A (zh) * | 2019-09-27 | 2022-04-12 | 强生消费者公司 | 凝胶咀嚼剂型 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it |
| GB8904182D0 (en) * | 1989-02-23 | 1989-04-05 | Glaxo Canada | Pharmaceutical compositions |
| US5229137A (en) * | 1992-05-06 | 1993-07-20 | Brigham And Women's Hospital, Inc. | Methods and pharmaceutical compositions for treating episodic heartburn |
| GB9224855D0 (en) * | 1992-11-27 | 1993-01-13 | Smithkline Beecham Plc | Pharmaceutical compositions |
| WO1995001780A1 (en) * | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | H2 antagonist-alginate combinations |
| US5976578A (en) * | 1996-10-10 | 1999-11-02 | Mcneil-Ppc, Inc. | Liquid antacid compositions |
| GB2338896B (en) * | 1998-07-02 | 2003-05-21 | Reckitt & Colmann Prod Ltd | Chewable Capsules |
| US6260735B1 (en) * | 2000-05-12 | 2001-07-17 | Colgate-Palmolive Company | Uniform dispensing dual chamber sachet |
| AU2006304180A1 (en) * | 2005-10-14 | 2007-04-26 | Microdose Therapeutx, Inc. | Pharmaceutical packaging of an oral dosage combination |
| WO2007102726A1 (es) | 2006-03-09 | 2007-09-13 | World-Trade Import-Export, Wtie, Ag. | Combinacion sinergica de inhibidores de receptores h2, silicon inerte y un complejo aluminato de hidroximagnesio |
| MXPA06010972A (es) * | 2006-09-25 | 2009-04-17 | World Trade Imp Export Wtie Ag | Proceso para estabilizacion de famotidina. |
| GB2494439A (en) * | 2011-09-09 | 2013-03-13 | Nova Bio Pharma Technologies Ltd | 6-Mercaptopurine oral suspension for the treatment of acute lymphoblastic leukaemia |
| US20130287899A1 (en) * | 2012-04-25 | 2013-10-31 | Avid Health, Inc. | Center-in-shell chewable compositions with functional components |
-
2017
- 2017-10-30 CN CN201780067474.XA patent/CN109890368B/zh active Active
- 2017-10-30 RU RU2019116746A patent/RU2761346C2/ru active
- 2017-10-30 MA MA046713A patent/MA46713A/fr unknown
- 2017-10-30 WO PCT/IB2017/056730 patent/WO2018083583A1/en unknown
- 2017-10-30 DK DK17817874.5T patent/DK3534880T3/da active
- 2017-10-30 CA CA3042466A patent/CA3042466A1/en active Pending
- 2017-10-30 AU AU2017353968A patent/AU2017353968B2/en active Active
- 2017-10-30 US US16/341,102 patent/US20200038376A1/en not_active Abandoned
- 2017-10-30 EP EP17817874.5A patent/EP3534880B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200038376A1 (en) | 2020-02-06 |
| CA3042466A1 (en) | 2018-05-11 |
| CN109890368A (zh) | 2019-06-14 |
| RU2019116746A (ru) | 2020-12-03 |
| MA46713A (fr) | 2019-09-11 |
| RU2761346C2 (ru) | 2021-12-07 |
| CN109890368B (zh) | 2021-12-21 |
| RU2019116746A3 (da) | 2021-01-29 |
| EP3534880A1 (en) | 2019-09-11 |
| EP3534880B1 (en) | 2022-05-18 |
| WO2018083583A1 (en) | 2018-05-11 |
| AU2017353968A1 (en) | 2019-05-02 |
| AU2017353968B2 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY4595S (es) | Dispositivo portátil de administración de fármacos | |
| DK3458102T3 (da) | Anti-cmet-antistoflægemiddelkonjugater og fremgangsmåder til anvendelse deraf | |
| UA37801S (uk) | Пристрій для інтраназального введення ліків | |
| ES2631504R1 (es) | Medicamentos de administración nasal y métodos para su uso | |
| DK3302641T3 (da) | Hørbar indikator til en lægemiddeladministrationsanordning | |
| DK3329217T3 (da) | Sensoranordning til en lægemiddeladministrationsanordning | |
| DK3519018T3 (da) | Medikamentadministrationsanordning | |
| DK3727555T3 (da) | Oral delivery of active drug substances | |
| DK3099356T3 (da) | Medikamentadministrationsanordning | |
| CL2018002870A1 (es) | Procedimiento y aparato para proporcionar un régimen de dosificación farmacocinética de drogas. | |
| DK3380139T3 (da) | Medikamentadministrationsanordning | |
| DK2621477T3 (da) | Oral farmaceutisk tablet til kontrolleret afgivelse af mesalazin og fremgangsmåde til opnåelse deraf | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| DK3380146T3 (da) | Medikamentadministrationsanordning | |
| DK3400045T3 (da) | Medikamentadministrationsanordning | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| DK3596069T3 (da) | Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil | |
| MA44720A (fr) | Comprimés à désintégration orale | |
| DK3534880T3 (da) | Flydende oral farmaceutisk dosisform omfattende en histamin-h2-receptor-antagonist og et syreneutraliserende middel | |
| DK3496783T3 (da) | Medikamentadministrationsanordning | |
| DK3558423T3 (da) | Medikamentadministrationsanordning | |
| DK3129057T3 (da) | Glykolipider og farmaceutiske sammensætninger deraf til anvendelse i terapi | |
| DK3057589T3 (da) | (s)-pirlindol og farmaceutisk acceptable salte heraf til anvendelse i medicin | |
| DK3349825T3 (da) | Lægemiddeladministrationsanordning | |
| MA49618A (fr) | Inhibiteurs de la mpo destinés à être utilisés en médecine |